22 December 2010


(“Sareum” or the “Company”)

Issue of Options

The Company announces that it has granted the following share options (the “Options”) to Tim Mitchell (Chief Executive Officer) and John Reader (Chief Scientific Officer) (together, the “Directors”);


Number of options

Tim Mitchell


John Reader


The Options have been granted with an exercise price of 0.26 pence.

Of the Options granted to each Director, 3,076,923 will vest immediately and are exercisable until 22 December 2020. The remaining 3,076,923 options will vest, subject to the discretion of the Remuneration Committee of the Company, on the date upon which a significant commercial deal is signed by the Company and are thereafter capable of being exercised until 22 December 2020.

In addition to the options being granted the Directors currently each hold options over 6,400,000 shares, which were granted on 4 December 2009


Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant Securities Limited (Nominated Adviser)

Simon Clements/Bidhi Bhoma

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.

Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk